{"slug":"kidney","tag":"kidney","variants":["kidney"],"description":"No description yet","count":3,"kinds":{"person":2,"trial":1},"related":[{"slug":"australia","tag":"australia","shared":1},{"slug":"paediatric","tag":"paediatric","shared":1},{"slug":"radiotherapy","tag":"radiotherapy","shared":1},{"slug":"sbrt","tag":"sbrt","shared":1},{"slug":"targeted-therapy","tag":"targeted-therapy","shared":1},{"slug":"trialist","tag":"trialist","shared":1}],"records":[{"id":"shankar-siva","kind":"person","name":"Shankar Siva","route":"/people/shankar-siva/","tldr":"Radiation oncologist who established stereotactic radiotherapy as a non-surgical option for primary kidney cancer."},{"id":"eric-jonasch","kind":"person","name":"Eric Jonasch","route":"/people/eric-jonasch/","tldr":"Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas."},{"id":"aren0533","kind":"trial","name":"COG AREN0533","route":"/trials/aren0533/","status":"positive","tldr":"A risk-adapted Wilms tumour trial: children whose lung metastases vanished after six weeks of chemotherapy were spared lung radiation, while those with stubborn nodules or a high-risk chromosome pattern got stronger chemotherapy and did better than in the past."}]}